Principal Financial Group
ABCL icon

Principal Financial Group’s AbCellera Biologics ABCL Stock Holding History

Principal Financial Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34,204
Closed -$155K – 2362
2024
Q1 		$155K Sell
34,204
-76,984
-69% -$393K ﹤0.01% 2213
2023
Q4 		$635K Buy
111,188
+18,217
+20% +$84.4K ﹤0.01% 1908
2023
Q3 		$428K Buy
92,971
+20,450
+28% +$124K ﹤0.01% 1983
2023
Q2 		$468K Buy
72,521
+24,473
+51% +$167K ﹤0.01% 1971
2023
Q1 		$362K Sell
48,048
-983
-2% -$8.93K ﹤0.01% 2046
2022
Q4 		$497K Buy
49,031
+23,906
+95% +$276K ﹤0.01% 1977
2022
Q3 		$248K Buy
25,125
+5,222
+26% +$57.3K ﹤0.01% 2146
2022
Q2 		$212K Buy
+19,903
New +$169K ﹤0.01% 2286

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Principal Financial Group's ABCL Position: Q2 2024 in Review

Principal Financial Group sold out of AbCellera Biologics (ABCL) in Q2 2024, closing a stake of 34,204 shares — an estimated $155K sold.

Principal Financial Group first reported a position in ABCL in Q2 2022 and held it in 8 quarters. The position peaked at $635K in Q4 2023. 147 funds tracked by Wall St. Rank hold ABCL as of Q2 2024.

  • Principal Financial Group reported no remaining AbCellera Biologics position as of Q2 2024 after selling out during the quarter.
  • Principal Financial Group sold 34,204 AbCellera Biologics shares in Q2 2024, an estimated $155K.
  • Principal Financial Group first reported a position in AbCellera Biologics in Q2 2022 and held it in 8 quarters.
  • Principal Financial Group's AbCellera Biologics position peaked at $635K in Q4 2023.
  • 147 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2024.

Based on Principal Financial Group's 13F filing for Q2 2024, filed 29 Jul 2024.